Current Report · Items 5.02 · 8-K
Chrome Holding Co.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, on March 23, 2025, Chrome Holding Co.…
Company context
23andMe is a genetics-led consumer healthcare company empowering a healthier future. For more information, please visit www.23andme.com.
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously disclosed, on March 23, 2025, Chrome Holding Co. (formerly known as 23andMe Holding Co.), a Delaware corporation (the “Company”), and certain of its subsidiaries (together with the Company, the “Debtors”) filed voluntary petitions seeking relief under Chapter 11 of Title 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Eastern District of Missouri (the “Court”).
As previously disclosed, on July 14, 2025, the Company and 23andMe Research Institute (formerly known as TTAM Research Institute), a California nonprofit public benefit corporation (“Research Institute”), consummated the transactions contemplated by that certain Asset Purchase Agreement, by and among the Debtors and Research Institute, dated as of June 13, 2025, whereby Research Institute acquired substantially all of the Debtors’ assets (the “Transaction”). Following the consummation of the Transaction, effective August 16, 2025, Research Institute appointed Joseph Selsavage, the Company’s Interim Chief Executive Officer and Chief Financial and Accounting Officer (the “CEO/CFAO”), as its Chief Financial Officer. Mr. Selsavage will continue to serve as the Company’s CEO/CFAO while serving as Research Institute’s Chief Financial Officer (the “Dual Service”) until the effective date of a Court-approved Chapter 11 plan or such later date as may be agreed among the Company and Mr. Selsavage (the “End Date”).
On August 21, 2025 (the “Effective Date” and, the period beginning on the Effective Date and ending on the End Date, the “Transition Period”), the Special Committee (the “Committee”) of the Board of Directors of the Company approved certain changes to Mr. Selsavage’s compensation in connection with the Dual Service. Specifically, during the Transition Period, Mr. Selsavage will be entitled to receive 75% of his current annual base salary rate of $600,000 for his service as the CEO/CFAO of the Company. On the Effective Date, the Committee also approved changing Mr. Selsavage’s title from “Interim Chief Executive Officer and Chief Financial and Accounting Officer” to “Chief Executive Officer and Chief Financial and Accounting Officer.”